Autoimmune Treatment Market Shaped by Innovations in Clinical Trial Platforms

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

From Its 2026 Market Size, What Value Is The Autoimmune Treatment Market Projected To Reach By 2030?

The autoimmune treatment market size has experienced rapid expansion in recent years. This market is projected to expand from $8.63 billion in 2025 to $9.84 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 14.0%. Historically, this growth has been driven by factors such as the enhanced availability of immunosuppressive drugs, the broadening of rheumatology and immunology services, increasing clinical expertise in autoimmune care, higher patient diagnosis rates, and expanded access to specialty medications.

The autoimmune treatment market size is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach $16.53 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.9%. Factors contributing to this growth during the projection period include heightened investment in the development of novel biologics, an increasing need for personalized autoimmune therapies, the broadened availability of digital monitoring and follow-up care, an intensified focus on mitigating long-term disease complications, and augmented research into immune system modulation. Key trends identified for the forecast period encompass the wider adoption of biologic therapies, a greater utilization of targeted immunomodulators, the increasing incorporation of long-term disease management programs, an expansion of personalized treatment regimens, and an elevated emphasis on combination drug therapies.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report

What Key Drivers Are Fueling The Growth Of The Autoimmune Treatment Market?

The expansion of healthcare expenditures is anticipated to boost the autoimmune treatment market. These expenditures encompass all costs related to providing health services, family planning, nutrition programs, and health-oriented emergency assistance. An increase in healthcare spending would facilitate the creation of more effective therapies and advanced medical technologies for autoimmune conditions. For example, forecasts from the Office for Budget Responsibility (OBR) and Treasury project the UK’s planned health expenditure to climb to £192 billion ($244.43 billion) in 2024/25, an increase from £182 billion ($231.70 billion) in 2022/23. Concurrently, data from the National Health Expenditures Accounts (NHEA), compiled by KFF, a US-based independent health policy research organization, indicates that health spending in the United States is predicted to grow by 5% from 2023 to 2024, reaching $4.9 trillion. Consequently, the growth in healthcare expenditures is a key driver for the autoimmune treatment market.

What Are The Main Segments Within The Autoimmune Treatment Market Segment Structure?

The autoimmune treatment market covered in this report is segmented –

1) By Service Type: Consultation And Diagnosis, Therapy And Monitoring, Drug development

2) By Disease: Rheumatoid Arthritis, Systemic Lupus Erythematosus, Sjögren’s Syndrome, Thyroiditis, Scleroderma, Other Diseases

3) By Application: Disease Management and Symptom Control, Disease Diagnosis and Monitoring, Immune Modulation and Targeted Therapy, Long-Term Care and Relapse Prevention

Subsegments:

1) By Consultation and Diagnosis: Clinical Evaluation and Medical Consultation, Autoimmune Biomarker Testing and Serological Assays, Imaging and Functional Diagnostic Services, Disease Severity Assessment and Risk Stratification

2) By Therapy and Monitoring: Pharmacological Treatment Management, Biologic and Immunotherapy Administration, Disease Activity Monitoring and Follow-Up Services, Adverse Event and Safety Monitoring, Patient Support and Adherence Programs

3) By Drug Development: Preclinical Research and Target Identification, Clinical Trial Services (Phase I–IV), Regulatory Affairs and Compliance Services, Pharmacovigilance and Post-Marketing Surveillance

What Trends Are Influencing The Autoimmune Treatment Market?

Leading entities within the autoimmune treatment market are intensifying efforts to launch advanced clinical trial platforms, aiming for a competitive advantage. These cutting-edge platforms in autoimmune treatment utilize sophisticated technologies and tailored strategies to improve effectiveness, safety, and results for patients. An example of this is the Scleroderma Research Foundation, a US-based non-profit organization, which introduced the CONQUEST trial platform in August 2023. The objective of the CONQUEST program is to further research and therapeutic options for scleroderma, a rare autoimmune condition impacting connective tissues. This initiative tackles crucial challenges in clinical development, facilitating progress in scleroderma treatments. Unique among rare autoimmune diseases, the CONQUEST platform clinical trial is structured to rapidly assess prospective therapies for interstitial lung disease associated with systemic sclerosis (SSc-ILD), alongside overall SSc outcomes, encompassing those related to skin and various other disease facets.

Who Are The Companies Participating In The Autoimmune Treatment Market?

Major companies operating in the autoimmune treatment market are Abbott Laboratories, Amgen Inc., Eli Lilly and Company, Pfizer Inc., F Hoffmann-La Roche AG, AstraZeneca PLC, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Biogen Idec Inc., GSK PLC, Genentech Inc., AbbVie Inc., Celgene Corporation, Gilead Sciences Inc., Merck & Co. Inc., Novartis International AG, Sanofi SA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB SA, Alexion Pharmaceuticals Inc., AnaptysBio Inc., Apellis Pharmaceuticals Inc., Arena Pharmaceuticals Inc., Aurinia Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Cabaletta Bio Inc., ChemoCentryx Inc., Corbus Pharmaceuticals Holdings Inc., CSL Limited

Get The Full Autoimmune Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report

Which Region Has The Greatest Market Share In The Autoimmune Treatment Market?

North America was the largest region in the autoimmune treatment market in 2025. The regions covered in the autoimmune treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Autoimmune Treatment Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report

Browse Through More Reports Similar to the Global Autoimmune Treatment Market 2026, By The Business Research Company

Systemic Lupus Erythematosus Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/systemic-lupus-erythematosus-treatment-global-market-report

Autoimmune Disease Diagnosis Market Report 2026

https://www.thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report

Veterinary Autoimmune Disease Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-autoimmune-disease-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795